Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.35 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL860193 | 0.92 | C5AR1 (0.35) | GPBAR1AKR1C3AKR1C2DGAT1BRAF | |
| Trifluoroacetic Acid SCHEMBL14631859 | 0.80 | DPP4 (0.40) | AKR1C3AKR1C2AKR1C4AKR1C1AKR1B10 | |
| Trifluoroacetic Acid SCHEMBL841644 | 0.79 | HTT (0.43) | AKR1C3AKR1C2 | |
| SCHEMBL840956 | 0.74 | BRAF (0.42) | GPBAR1AKR1C3AKR1C2BRAFMLYCD | |
| SCHEMBL13812978 | 0.73 | GLA (0.43) | GPBAR1DGAT1BRAFSLC6A2SLC6A4 | |
| Acetic Acid SCHEMBL841156 | 0.71 | F7 (0.47) | — | |
| SCHEMBL860763 | 0.71 | F7 (0.49) | — | |
| SCHEMBL3641864 | 0.70 | PDE2A (0.35) | AKR1C3AKR1C2AKR1C4AKR1C1AKR1B10 | |
| SCHEMBL860439 | 0.69 | AR (0.40) | — | |
| SCHEMBL3058229 | 0.69 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | GPBAR1 3856/4885AKR1C3 628/4885AKR1C2 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.